Literature DB >> 21849112

[Comparisons of epidemiological and clinical characteristics in children with hand-foot-mouth disease caused by Enterovirus 71 and Coxackievirus A16].

Lei Jia1, Cheng-Song Zhao, Li Zhang, Shuang Li, Dai-Tao Zhang, Bai-Wei Liu, Quan-Yi Wang, Xin-Yu Li.   

Abstract

OBJECTIVE: To compare the differences of epidemiological and clinical characteristics in children with hand-foot-mouth disease (HFMD) caused by Coxsackievirus A16 (CA16) and Enterovirus 71 (EV71).
METHODS: The samples of vesicle fluid and throat swabs of 108 children with HFMD were collected and detected for enterovirus by RT-PCR. The clinical data of children with EV71 and CA16 infection were retrospectively reviewed and compared.
RESULTS: The total positive rate of enterovirus was 97.2% (105/108). Of the 105 cases, 56 cases were positive for EV71 (51.9%), 39 cases were positive for CA16 (36.1%), 2 cases were positive for other enterovirus (1.9%), and 8 cases were co-infected by EV71 and CA16 (7.4%). There were no significant differences in age and sex between EV71 and CV16 infected cases. The univariate analysis showed that the incidences of herpes of mouth, erythra of knees, and nose running in children infected by CA16 were higher than in those infected by EV71. The multivariate logistic regression analysis showed that the HFMD children who had erythra of knees had higher probability of CA16 infection.
CONCLUSIONS: EV71 should be considered as the pathogen in children with HFMD who have no herpes of mouth, erythra of knees, and nose running.

Entities:  

Mesh:

Year:  2011        PMID: 21849112

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  7 in total

1.  Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line.

Authors:  Erxia Yang; Chen Cheng; Ying Zhang; Jingjing Wang; Yanchun Che; Jing Pu; Chenghong Dong; Longding Liu; Zhanlong He; Shuaiyao Lu; Yuan Zhao; Li Jiang; Yun Liao; Congwen Shao; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-02-28       Impact factor: 3.452

Review 2.  Coxsackievirus A16: epidemiology, diagnosis, and vaccine.

Authors:  Qunying Mao; Yiping Wang; Xin Yao; Lianlian Bian; Xing Wu; Miao Xu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2013-11-14       Impact factor: 3.452

3.  A neonatal mouse model of coxsackievirus A16 for vaccine evaluation.

Authors:  Qunying Mao; Yiping Wang; Rong Gao; Jie Shao; Xin Yao; Shuhui Lang; Chao Wang; Panyong Mao; Zhenglun Liang; Junzhi Wang
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

4.  Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants.

Authors:  Feng-Cai Zhu; Zheng-Lun Liang; Fan-Yue Meng; Ying Zeng; Qun-Ying Mao; Kai Chu; Xue-Fang Song; Xin Yao; Jing-Xin Li; Hong Ji; Yi-Ju Zhang; Liang Li; Hong-Xing Pan; Ke Xu; Wei-Ming Dai; Wei-Wei Zhang; Fei Deng; Hua Wang; Jun-Zhi Wang
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

5.  Coxsackievirus A16 infection induces neural cell and non-neural cell apoptosis in vitro.

Authors:  Zhaolong Li; Jinghua Yu; Li Liu; Zhenhong Wei; Elana S Ehrlich; Guanchen Liu; Jingliang Li; Xin Liu; Hong Wang; Xiao-fang Yu; Wenyan Zhang
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

6.  Proteomic analysis of extremely severe hand, foot and mouth disease infected by enterovirus 71.

Authors:  Li Deng; Hong-Ling Jia; Chao-Wu Liu; Yu-Fen Xu; Li-Jia Mao; Chun-Hui He; Gen-Quan Yin; Jun-Hong Lin; Jian-Ping Tao; Li Zhu
Journal:  BMC Infect Dis       Date:  2013-08-20       Impact factor: 3.090

7.  Molecular epidemiology of coxsackievirus A16: intratype and prevalent intertype recombination identified.

Authors:  Xiangpeng Chen; Xiaojuan Tan; Jing Li; Yu Jin; Liming Gong; Mei Hong; Yonglin Shi; Shuangli Zhu; Baomin Zhang; Shuang Zhang; Yong Zhang; Naiying Mao; Wenbo Xu
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.